Navigation Links
Certain Drug Combinations May Beat Back Aggressive Breast Cancer
Date:12/13/2010

By Maureen Salamon
HealthDay Reporter

FRIDAY, Dec. 10 (HealthDay News) -- Combinations of targeted therapies for an especially aggressive type of breast cancer could potentially usher the majority of affected patients into remission, researchers at a major breast cancer meeting said Friday.

Presenting results from three trials at the annual San Antonio Breast Cancer Symposium, scientists explained that administering two or more drugs designed to treat HER2-positive tumors resulted in much higher remission rates than doses of any one drug or standard chemotherapy alone.

Given to patients several weeks before cancer surgery, with or without chemotherapy, the medications often shrank tumors dramatically or eradicated them altogether, the researchers said.

HER2-positive cancer is receptive to a protein called human epidermal growth factor receptor 2, which promotes the growth of malignant cells. Drugs that specifically target HER2 cells -- including Herceptin, Tykerb and pertuzumab -- have been proven effective on these types of tumors, which tend to be more aggressive than other breast cancers.

"I think it's a very exciting era, because we've gone from a very lethal era . . . to a point where we might be able to cure this disease," said Dr. Neil Spector, a professor of medicine at Duke University Medical Center, who moderated the symposium session.

Using Tykerb and Herceptin combined with chemotherapy before surgery, researchers followed 2,500 women with early breast cancer at 85 facilities throughout Germany. About half of these patients achieved remission before surgery, said Dr. Michael Untch, head of the multidisciplinary breast cancer department at Helios Clinic in Berlin.

"In a majority of these patients, we could do breast-conserving surgery where previously they were candidates for mastectomy," Untch said.

The team will continue following the patients to see if remission at surgery affects their outcome.

Another study showed the combination of pertuzumab and Herceptin, when given with the chemotherapy drug docetaxel, eradicated 46 percent of tumors, 50 percent more than the results achieved without pertuzumab. Also, 17 percent of tumors were eradicated by combining the two targeted drugs and skipping chemotherapy, the researchers said.

"Our study is the only one that has tested the hypothesis that [pertuzumab and Herceptin] could work without chemotherapy in these women," said lead researcher Dr. Luca Gianni, director of medical oncology at the Fondazione IRCCS Istituto Nationale Tumori Fondazione IRCCS Istituto di Milano in Italy.

The third study, which included 455 patients followed at 99 sites for nearly two years, indicated that a combination of Tykerb, Herceptin and the chemotherapy drug Taxol improved tumor response rates significantly more than any of the drugs alone.

The mix led to a 51 percent remission rate, compared to 29 percent for a single therapy, said lead researcher Dr. Jose Baselga, chief of the division of hematology and oncology and associate director of the Massachusetts General Hospital Cancer Center.

"With these new therapies, we could easily go to curing over 90 percent of these patients, which is remarkable since this was the most lethal kind of breast cancer 10 years ago," said Baselga.

"This is a very fast advancement of new therapies," Untch agreed.

Researchers countered negative side effects of the drugs, which included diarrhea, liver function abnormalities, skin disorders and a low white blood cell count, by lowering patients' dosages or administering additional medications to alleviate specific symptoms.

Describing targeted therapies as a "HER2 blockade," Spector said if cost was not an issue, he would use all three drugs on HER2-positive breast cancer patients.

Discussing the high cost of treatment at the session, the researchers noted that spending more money on faster-acting, more effective treatments could save other treatment expenditures down the line.

"I do think we need to be creative in the ways we [run through] this data to make things more affordable," Spector said.

Because this study was presented at a medical meeting, the findings should be viewed as preliminary until they are published in a peer-reviewed journal.

More information

To learn more about surgical options for breast cancer, visit the American Cancer Society.

SOURCES: Neil Spector, M.D., professor of medicine, Duke University Medical Center, Durham, N.C.; Michael Untch, M.D., head of multidisciplinary breast cancer department, Helios Clinic, Berlin, Germany; Luca Gianni, M.D., director, medical oncology, Fondazione IRCCS Istituto di Milano, Italy; Jose Baselga, M.D., Ph.D., chief, division of hematology and oncology, associate director, Massachusetts General Hospital Cancer Center, Boston; San Antonio Breast Cancer Symposium, Dec. 10, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
2. Certain pain medications do not appear to be associated with skin cancer risk
3. AGA offers new recommendations for CRC surveillance for certain patients with IBD
4. Smoking significantly increases risk of aneurysm in people with certain genes
5. American Stroke Association Late-Breaking Science Report: Surgery, Stenting to Open Blocked Neck Arteries Similar in Safety, Efficacy, But Show Differences in Stroke, Heart Attack and Death Rates at Certain Ages
6. Certain Bone Drugs May Lower Breast Cancer Risk
7. Football Injuries More Likely on Certain Artificial Turf
8. Plavix Can Help Cut Death Risk in Certain Heart Patients
9. The Worst Is Over, but the Road to Growth Is Uncertain - The 17th Annual CFO Rising Conference & Exhibition
10. Perhaps a longer lifespan, certainly a longer health span
11. One in Five Parents Would Spank in Certain Settings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Certain Drug Combinations May Beat Back Aggressive Breast Cancer
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: